Amplify CWP Growth & Income ETF (QDVO)
ARCA ARCA Primary Summary
QDVO Chart
QDVO's 32% Return Masks a Hidden Risk for Income Investors
Amplify CWP Growth & Income ETF (NYSEARCA:QDVO) sits in an awkward niche: it pays a monthly distribution funded partly by call-option premiums, yet the portfolio underneath is essentially a mega-cap technology growth fund.
Amplify's QDVO Turned Magnificent Seven Stocks Into a 10.7% Income Machine
Monthly income checks from a portfolio of NVIDIA, Apple, Microsoft, and Alphabet sound appealing until you realize those same stocks have compounded at extraordinary rates for a decade.
QDVO: When To Reinvest And Buy More Shares
Amplify CWP Growth & Income ETF maintains a 'Buy' rating, offering a 10.7% yield amid growth stock volatility. QDVO's concentrated, actively managed portfolio of 20-40 mega-cap tech stocks emphasizes out-of-the-money covered calls for income and growth. Recent performance has lagged the S&P 500, with QDVO and NASDAQ 100 both down ~1% over six months, highlighting the similar volatility and the need for protection.
Amplify CWP Growth & Income ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YA Yinka Akinsola Blue Trust Inc. | 4,086 | $108,891.9 | $122,028.39 | $13,136.49 | 12.06% |
| PIL PFG Investments LLC PFG Investments LLC | 11,847 | $343,512.34 | $353,455.24 | $9,942.9 | 2.89% |
 Joseph C. Gissy Tactive Advisors, LLC | 26,577 | $710,918.53 | $793,323.45 | $82,404.92 | 11.59% |
 Jon Deven Mouton CAP Partners, LLC | 16,691 | $472,065.52 | $498,476.71 | $26,411.19 | 5.59% |
| WBC William Bradley Clayton Sagespring Wealth Partners LLC | 88,850 | $2.37M | $2.62M | $248,778.5 | 10.51% |
Amplify CWP Growth & Income ETF (QDVO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Amplify CWP Growth & Income ETF ever had a stock split?
Amplify CWP Growth & Income ETF Profile
| ARCA Exchange | US Country |
Overview
The fund is dedicated to investing a substantial portion of its assets, specifically at least 80%, in securities that are integral to the index it follows. This index consists of global companies engaged in the manufacturing of GLP-1 agonist pharmaceuticals or in supporting this sector. GLP-1 agonists are a class of medications known for their ability to lower blood sugar levels, reduce appetite, and promote a feeling of fullness, leading potentially to weight loss. Operating with a focus on a specific segment of the pharmaceutical industry, the fund is characterized by its non-diversified status, meaning it may invest more heavily in fewer securities, which can both increase the potential for higher returns and pose a higher risk of volatility.
Products and Services
- GLP-1 Agonist Pharmaceuticals
This product category includes medications developed to mimic the action of the GLP-1 hormone, which is naturally present in the body. These medications work by stimulating insulin release in response to high blood glucose levels, inhibiting glucagon release, and slowing gastric emptying. By doing so, they effectively lower blood sugar levels. Additionally, they help control appetite and promote a sense of fullness, which can assist in weight management. The fund invests in companies that either directly manufacture these pharmaceuticals or play a significant role in their development and distribution within the global market.
- Investment in Enabling Companies
Aside from direct investments in manufacturers of GLP-1 agonist pharmaceuticals, the fund also invests in companies that enable this sector. These enablers could include firms involved in the research and development of new GLP-1 compounds, companies providing specialty pharmaceutical services such as drug delivery technologies, or those involved in the broader logistics and distribution network necessary for bringing these products to market. By investing in these enablers, the fund supports the infrastructure necessary for the successful development, manufacturing, and distribution of GLP-1 agonist medications.
